UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.616

Sortiert nach

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

The American heart journal, 2007, Vol.153 (1), p.66.e9-66.e16

2007

Link zum Volltext

Verfügbarkeit prüfen

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

Journal of clinical pharmacology, 2008-04, Vol.48 (4), p.475-484

2008

Link zum Volltext

Verfügbarkeit prüfen

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

Journal of the American College of Cardiology, 2008-12, Vol.52 (24), p.1968-1977

2008

Link zum Volltext

Verfügbarkeit prüfen

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

Circulation (New York, N.Y.), 2009-05, Vol.119 (19), p.2553-2560

2009

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

Platelets (Edinburgh), 2006-06, Vol.17 (4), p.209-217

2006

Link zum Volltext

Verfügbarkeit prüfen

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

Journal of cardiovascular pharmacology, 2006-03, Vol.47 (3), p.377-384

2006

Link zum Volltext

Verfügbarkeit prüfen

Laboratory diagnosis of dysfibrinogenemia

Archives of pathology & laboratory medicine (1976), 2002-04, Vol.126 (4), p.499-505

2002

Link zum Volltext

Verfügbarkeit prüfen

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

European heart journal, 2006-05, Vol.27 (10), p.1166-1173

2006

Link zum Volltext

Verfügbarkeit prüfen

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

European heart journal, 2009-07, Vol.30 (14), p.1744-1752

2009

Link zum Volltext

Verfügbarkeit prüfen

Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease

Archives of pathology & laboratory medicine (1976), 2002-11, Vol.126 (11), p.1376-1381

Brandt, John T

2002

Link zum Volltext

Verfügbarkeit prüfen

D-dimer: simple test, tough problems

Archives of pathology & laboratory medicine (1976), 2013-08, Vol.137 (8), p.1030-1038

2013

Link zum Volltext

Verfügbarkeit prüfen

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

Platelets (Edinburgh), 2008-01, Vol.19 (4), p.275-281

2008

Link zum Volltext

Verfügbarkeit prüfen

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

The American heart journal, 2009-03, Vol.157 (3), p.562.e1-562.e9

2009

Link zum Volltext

Verfügbarkeit prüfen

Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

The American heart journal, 2009-03, Vol.157 (3), p.562-562.e9

2009

Link zum Volltext

Verfügbarkeit prüfen

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Journal of cardiovascular pharmacology, 2007-11, Vol.50 (5), p.555-562

2007

Link zum Volltext

Verfügbarkeit prüfen

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Investigational new drugs, 2013-08, Vol.31 (4), p.1023-1034

2013

Link zum Volltext

Verfügbarkeit prüfen

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

British journal of clinical pharmacology, 2007-04, Vol.63 (4), p.421-430

2007

Link zum Volltext

Verfügbarkeit prüfen

Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum

Journal of pharmaceutical and biomedical analysis, 2005-01, Vol.36 (5), p.1037-1044

2005

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

Platelets (Edinburgh), 2009-01, Vol.20 (5), p.316-327

2009

Link zum Volltext

Verfügbarkeit prüfen

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

Journal of cardiovascular pharmacology, 2007-03, Vol.49 (3), p.167-173

2007

Link zum Volltext

Verfügbarkeit prüfen

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy

Archives of pathology & laboratory medicine (1976), 1998-09, Vol.122 (9), p.782

1998

Link zum Volltext

Verfügbarkeit prüfen

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humans

Platelets (Edinburgh), 2006-06, Vol.17 (4), p.218-226

2006

Link zum Volltext

Verfügbarkeit prüfen

External Peer Review Quality Assurance Testing in von Willebrand Disease: The Recent Experience of the United States College of American Pathologists Proficiency Testing Program

Seminars in thrombosis and hemostasis, 2006-07, Vol.32 (5), p.499-504

2006

Link zum Volltext

Verfügbarkeit prüfen

Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing

Archives of pathology & laboratory medicine (1976), 2006-11, Vol.130 (11), p.1605-1611

2006

Link zum Volltext

Verfügbarkeit prüfen

Quality Assurance in Hemostasis: The Perspective from the College of American Pathologists Proficiency Testing Program

Seminars in thrombosis and hemostasis, 2007-04, Vol.33 (3), p.250-258

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.616

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.057)
Mit Volltextzugriff
(1.518)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects

Laboratory diagnosis of dysfibrinogenemia

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease

D-dimer: simple test, tough problems

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin

Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humans

External Peer Review Quality Assurance Testing in von Willebrand Disease: The Recent Experience of the United States College of American Pathologists Proficiency Testing Program

Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing

Quality Assurance in Hemostasis: The Perspective from the College of American Pathologists Proficiency Testing Program

Aktive Filter

Suchergebnisse filtern